Add to ORKGAmplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...
Glioblastoma multiforme is the most frequent, aggressive and fatal type of brain tumor. Glioblastoma...
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequ...
Glioma is the most common primary tumor of the nervous system, and approximately 50% of patients exh...
Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findi...
AbstractAberrant epidermal growth factor receptor (EGFR) signaling is common in cancer. Increased ex...
Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current co...
Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current co...
Glioblastoma is a particularly resilient cancer, and while therapies may be able to reach the brain ...
The tyrosine kinase receptor epidermal growth factor receptor (EGFR) can be activated by several lig...
Glioblastoma multiforme (GBM) is a highly lethal brain tumor for which little treatment is available...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Biological Engineering Division, 2008."Septe...
Glioblastoma is the most common and most aggressive form of malignant primary brain tumor in adults....
Epidermal growth factor receptor (EGFR) is highly amplified, mutated and overexpressed in human mali...
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...
Glioblastoma multiforme is the most frequent, aggressive and fatal type of brain tumor. Glioblastoma...
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequ...
Glioma is the most common primary tumor of the nervous system, and approximately 50% of patients exh...
Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findi...
AbstractAberrant epidermal growth factor receptor (EGFR) signaling is common in cancer. Increased ex...
Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current co...
Epidermal growth factor receptor (EGFR) and the mutant EGFRvIII are major focal points in current co...
Glioblastoma is a particularly resilient cancer, and while therapies may be able to reach the brain ...
The tyrosine kinase receptor epidermal growth factor receptor (EGFR) can be activated by several lig...
Glioblastoma multiforme (GBM) is a highly lethal brain tumor for which little treatment is available...
Thesis (Ph. D.)--Massachusetts Institute of Technology, Biological Engineering Division, 2008."Septe...
Glioblastoma is the most common and most aggressive form of malignant primary brain tumor in adults....
Epidermal growth factor receptor (EGFR) is highly amplified, mutated and overexpressed in human mali...
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...
Glioblastoma multiforme is the most frequent, aggressive and fatal type of brain tumor. Glioblastoma...
Targeted therapy against driver mutations responsible for cancer progression has been shown to be ef...